Last reviewed · How we verify
perineural Dexamethasone 4mg
At a glance
| Generic name | perineural Dexamethasone 4mg |
|---|---|
| Sponsor | Poznan University of Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Dexamethasone Administration Route in PENG Block for Pediatric Hip Surgery (PHASE4)
- PENG Block Optimization: Volume and Dexamethasone Effects (PHASE4)
- Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults (NA)
- Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA (NA)
- Impact of Dexamethasone Route on Pain and Inflammation in iPACK With ACB for Knee Arthroplasty (PHASE4)
- Prevention of Rebound Pain After Axillary Block (NA)
- Comparison of Perineural Dexamethasone Versus Dexmedetomidine as Adjuvants to Erector Spinae Plane Block in Lumbar Spine Surgery: A Randomized, Double-blind, Controlled Trial (PHASE4)
- The Effect of Dexamethasone Administration Route on Pain and Inflammatory Response in PENG Block for Total Hip Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- perineural Dexamethasone 4mg CI brief — competitive landscape report
- perineural Dexamethasone 4mg updates RSS · CI watch RSS
- Poznan University of Medical Sciences portfolio CI